白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的疗效及安全性分析

doi:10.3969/j.issn.1007-3969.2014.11.007

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (11): 836-845.doi: 10.3969/j.issn.1007-3969.2014.11.007

白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的疗效及安全性分析

梁旭,李惠平,邸立军,姜晗,宋国红,严颖,王超颖,邵彬,林晓琳

北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺肿瘤内科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142

出版日期:2014-11-30 发布日期:2015-05-05

Albumin-bound paclitaxel for treatment of patients with refractory metastatic breast cancer

LIANG Xu, LI Hui-ping, DI Li-jun, JIANG Han-fang, SONG Guo-hong, YAN Ying, WANG Chao-ying, SHAO Bin, LIN Xiao-lin

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Published:2014-11-30 Online:2015-05-05
Contact: LI Hui-ping E-mail: Huipingli2013@yahoo.com

摘要/Abstract

摘要：

背景与目的：白蛋白结合型紫杉醇通过将紫杉醇与人血白蛋白相结合新型制剂方式提高了紫杉醇的疗效，目前主要应用于疾病进展迅速或联合化疗后复发的晚期乳腺癌。本研究对白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的疗效和安全性进行探讨。方法：收集2009年7月—2014年1月在北京大学肿瘤医院接受白蛋白结合型紫杉醇单药或联合方案化疗的患者的临床资料，筛选疾病进展迅速和多线治疗后患者，每2个周期评价疗效，每周期评价不良反应，随访患者生存情况。结果：共58例难治性晚期乳腺癌患者入组，均可评价疗效，67.2%(39/58)为三线以上化疗患者，32.8%(19/58)接受一、二线解救化疗的均为辅助化疗后1年内复发、疾病进展迅速的患者，58例中84.5%的患者伴有内脏转移，93.1%的患者既往使用过紫杉类药物。化疗的客观有效率为13.8%(8/58)，临床控制率为60.3%(35/58)，中位无疾病进展时间为4.0个月，总生存时间为10.1个月。其中23例三阴性乳腺癌患者的客观有效率为13.0%，临床控制率56.5%，中位无疾病进展时间为4.1个月，总生存时间为6.6个月。3～4度不良反应主要为血液学毒性，中性粒细胞减低的发生率34.5%(20/58)，粒细胞缺乏性发热发生率5.2%(3/58)，贫血12.1%(7/58)，血小板减低6.9%(4/58)。结论：白蛋白结合型紫杉醇单药及联合方案是进展迅速或多线治疗失败的难治性晚期乳腺癌的一种治疗选择，对既往接受过紫杉类药物治疗和晚期三阴性乳腺癌也显示出一定疗效，且毒副作用可耐受。

关键词: 晚期难治性乳腺癌, 白蛋白紫杉醇, 疗效, 安全性

Abstract:

Background and purpose: Nab-paclitaxel (Abraxane) is an albumin-bound form of paclitaxel that utilizes the natural properties of albumin to improve paclitaxel delivery to the tumor. It has recently been approved for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within short time after adjuvant chemotherapy. The purpose of this study was to evaluate the efficacy and safety of albumin-bound paclitaxel in patients with aggressive and refractory metastatic breast cancer (MBC). Methods: A total of 58 patients with MBC were enrolled into this study from Jul. 2009 to Jan. 2014. All patients received albumin-bound paclitaxelbased chemotherapy. The adverse reactions were evaluated every cycle, and the short-term response was evaluated every two cycles. The patients were followed-up, and the survival was analyzed. Results: 58 patients with refractory MBC were evaluable for response, 67.2% of patients received multiple line (≥3 lines) chemotherapy, 32.8% of patients with first and second line of chemotherapy were involved metastasis within one year after adjuvant chemotherapy, 84.5% of patients with visceral metastasis and 93.1% with prior taxane treatment. The objective response rate (ORR) was 13.8%, and disease control rate (DCR) was 60.3%, the median progression free survival (PFS) was 4.0 months, and the overall survival (OS) was 10.1 months. For 23 patients with triple negative breast cancer, ORR was 13.0% and DCR was 56.5%, the median PFS was 4.1 months, and OS was 6.6 months. The main toxicity was myelosuppression (grades 3 and 4 neutropenia, anemia and thombocytopenia were seen in 34.5%, 12.1% and 6.9% of patients, respectively), gastrointestinal reactions, sensory neuropathy, myodynia/arthragia, fatigue, alopecia and so on. Conclusion: The albumin-bound paclitaxel-based chemotherapy can be used in aggressive and refractory MBC. It also showed antitumor activity in taxanes-resistance patients and triple negative patients with good safety and tolerance.

Key words: Refractory metastatic breast cancer, Albumin-bound paclitaxel, Effect, Safety

梁旭,李惠平,邸立军,姜晗,宋国红,严颖,王超颖,邵彬,林晓琳. 白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的疗效及安全性分析[J]. 中国癌症杂志, 2014, 24(11): 836-845.

LIANG Xu, LI Hui-ping, DI Li-jun, JIANG Han-fang, SONG Guo-hong, YAN Ying, WANG Chao-ying, SHAO Bin, LIN Xiao-lin. Albumin-bound paclitaxel for treatment of patients with refractory metastatic breast cancer[J]. China Oncology, 2014, 24(11): 836-845.

[1]	陆　立, 卢仁泉, 孙佳俊, 陆　凝, 郭　林. 血清N-MID在原发性肺癌患者骨转移辅助诊断和疗效监测中的应用分析[J]. 中国癌症杂志, 2021, 31(9): 838-844.
[2]	义维丽, 赵文成, 黄东宁, 覃　莉, 吴新天, 周　斐, 吴凤英 . PD-1单抗治疗非小细胞肺癌相关不良反应及其与疗效的相关性分析[J]. 中国癌症杂志, 2021, 31(3): 203-211.
[3]	武鸿文, 梅　艳, 王　乔, 袁　佳, 赵立威. 血清MIP-1α、S-TK1对于甲状腺癌术后放射性 ¹³¹ I治疗效果评估的临床价值[J]. 中国癌症杂志, 2021, 31(11): 1088-1095.
[4]	宁周雨, 花永强, 徐立涛, 庄丽萍, 冯兰云, 陈　颢, 王　鹏, 沈晔华, 林钧华, 陈　震, 孟志强. 白蛋白结合型紫杉醇联合吉西他滨动脉灌注治疗进展期胰腺癌的安全性和有效性回顾性研究[J]. 中国癌症杂志, 2020, 30(2): 128-134.
[5]	胡　磊, 董红军, 徐　浩, 袁毅方, 王耀华 . 喉部分切除术和经口内镜CO ₂ 激光显微手术治疗前联合阳性早期声门癌患者的疗效比较[J]. 中国癌症杂志, 2020, 30(2): 142-147.
[6]	孙健达，熊俊，张汉雄，陈意标. 血液标志物在局部晚期鼻咽癌中的预测价值[J]. 中国癌症杂志, 2019, 29(7): 528-534.
[7]	李静文，周　严，曹淑慧，王　悦，钟　华. 纳武单抗对晚期非小细胞肺癌的疗效和安全性的单中心分析[J]. 中国癌症杂志, 2019, 29(10): 803-808.
[8]	高志强,王韡旻,蔡雨晴,秦若琰,顾爱琴,熊丽纹,韩宝惠,姜丽岩,施春雷 . 奥希替尼治疗62例晚期肺腺癌患者的临床疗效观察[J]. 中国癌症杂志, 2019, 29(10): 809-814.
[9]	孙佳俊,卢仁泉,郑　慧,等. 血清HER2-ECD水平在乳腺癌新辅助化疗中的应用价值分析[J]. 中国癌症杂志, 2019, 29(1): 32-36.
[10]	杨佑琦,区晓敏,周　鑫,等. GP、PF及TPF方案化疗联合调强适形放疗治疗鼻咽癌的临床疗效[J]. 中国癌症杂志, 2018, 28(8): 602-608.
[11]	张迎强,张　鑫,王　宸,等. ¹⁸F-FDG PET/CT在阿帕替尼治疗肺多发转移性碘难治性分化型甲状腺癌评估中的价值[J]. 中国癌症杂志, 2018, 28(7): 505-510.
[12]	张腾,胡厚洋,柏庆花,等. 慢性淋巴细胞性甲状腺炎对分化型甲状腺癌放射性碘清甲治疗效果的影响[J]. 中国癌症杂志, 2018, 28(6): 419-423.
[13]	周　迪,刘苓霜,姜　怡,等. 中医药联合甲磺酸阿帕替尼治疗Ⅳ期恶性肿瘤的单臂单中心临床研究[J]. 中国癌症杂志, 2018, 28(11): 833-839.
[14]	张　娜,梁　军,林岩松. 甲状腺球蛋白抗体对甲状腺乳头状癌¹³¹I清甲疗效的影响[J]. 中国癌症杂志, 2017, 27(6): 476-481.
[15]	胡厚洋,梁　军,张　腾,等. 分化型甲状腺癌被膜及被膜外微小侵犯与复发风险[J]. 中国癌症杂志, 2017, 27(12): 946-952.

白蛋白结合型紫杉醇治疗晚期难治性乳腺癌的疗效及安全性分析

Albumin-bound paclitaxel for treatment of patients with refractory metastatic breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价